drugset
drugset / Trial / NCT06838962

Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)

NCT06838962 ↗

Phase 2 Recruiting 30 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of primary immune thrombocytopenia in patients who have failed first-line treatment.

Timeline

Start
2024-08-01
Primary completion
2026-08
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Daratumumab Monoclonal antibody 16 mg/kg Intravenous

Indications

autoimmune thrombocytopenia